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Combining 5-ALA Fluorescence and Intraoperative
MRI in Glioblastoma Surgery: A Histology-Based
Evaluation
BACKGROUND: Glioblastoma resection guided by 5-aminolevulinic acid (5-ALA) fluo-
rescence and intraoperative magnetic resonance imaging (iMRI) may improve surgical
results and prolong survival.
OBJECTIVE: To evaluate 5-ALA fluorescence combined with subsequent low-field iMRI
for resection control in glioblastoma surgery.
METHODS: Fourteen patients with suspected glioblastoma suitable for complete
resection of contrast-enhancing portions were enrolled. The surgery was carried out
using 5-ALA–induced fluorescence and frameless navigation. Areas suspicious for tumor
underwent biopsy. After complete resection of fluorescent tissue, low-field iMRI was
performed. Areas suspicious for tumor remnant underwent biopsy under navigation
guidance and were resected. The histological analysis was blinded.
RESULTS: In 13 of 14 cases, the diagnosis was glioblastoma multiforme. One lym-
phoma and 1 case without fluorescence were excluded. In 11 of 12 operations, residual
contrast enhancement on iMRI was found after complete resection of 5-ALA fluorescent
tissue. In 1 case, the iMRI enhancement was in an eloquent area and did not undergo
a biopsy. The 28 biopsies of areas suspicious for tumor on iMRI in the remaining 10
cases showed tumor in 39.3%, infiltration zone in 25%, reactive central nervous system
tissue in 32.1%, and normal brain in 3.6%.
CONCLUSION: 5-ALA fluorescence–guided resection may leave some glioblastoma
tissue undetected. MRI might detect areas suspicious for tumor even after complete
resection of all fluorescent tissue; however, due to the limited accuracy of iMRI in
predicting tumor remnant (64.3%), resection of this tissue has to be considered with
caution in eloquent regions.
KEY WORDS: 5-ALA fluorescence, Glioblastoma, Intraoperative magnetic resonance imaging, Resection
control
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P
rolongation of survival in glioblastoma
patients is related to the degree of resec-
tion.1-5 Gross total resection (98% of
tumor mass) improves outcome, and even tumor
reduction of 78% has been shown to increase
survival and the success of adjuvant therapy.6-9
The degree of resection is thus of the greatest
importance, but tumor heterogeneity and the
infiltrative nature of glioma cells can make it
difficult to achieve radical resection without
inducing neurological deficits.10,11
Different imaging modalities have been inves-
tigated with respect to their accuracy in tumor
visualization. 5-Aminolevulinic acid (5-ALA)–
derived fluorescence as an intraoperative visual
marker has proved to be especially helpful and
has already become the standard of care in some
institutions.5,12-15 The evidence that the use of
5-ALA leads to a significantly higher rate of
complete resection of contrast-enhancing tumor
(CRET) and increased progression-free survival
at 6 months was demonstrated in a randomized,
controlled multicenter trial in 2006.13 Intra-
operative MRI (iMRI) for glioblastoma resection
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control has been investigated by several groups since 199616,17
and has facilitated increased resection rates in low- and high-grade
gliomas.18-20 iMRI provides information about the intraoperative
structural anatomy and guides navigation toward suspected areas
of remnant tumor independent of surgery-related brain shift.21-25
Both 5-ALA fluorescence and iMRI have their own set of
limitations. Common to both is the problem of clearly
delineating the boundary between the infiltration zone and
healthy tissue.
In this study, we combined the 2 techniques in a series of
operations in order to optimize the degree of resection. Using
histological samples as a reference, we first assessed the accuracy of
5-ALA fluorescence in detecting tumor tissue during fluorescence-
guided resection. On complete resection of all 5-ALA fluorescent
tumor tissue, we performed iMRI and assessed its accuracy in
detecting remnant tumor.
METHODS
We included patients operated on at the University Hospital Zurich,
Switzerland, between August 2009 and June 2011 with a primary
diagnosis of glioblastoma (no other tumor entity, metastases, recurrent
glioblastoma, or malignant transformation of a previously known lower
grade glioma). Patients were only enrolled if the T1 contrast-enhancing
areas on preoperative MRI were considered completely resectable, taking
into account the anatomic location of the tumor. Tumors extending into
the primary motor cortex, language- and speech-processing cortex, the
internal capsule, basal ganglia, thalamus, skull base, and brainstem were
excluded.
The study was approved for 14 patients (Table 1) by the Zurich State
Ethics Committee (reference no. E229/2009).
Equipment
The equipment used for all 14 operations included an OMPI Pentero
microscope with a blue-light setting at 400 to 410 nm (Carl Zeiss,
Oberkochen Germany), a PoleStar N30 iMRI system (0.15 T) with
a StealthStation S7 integrated navigational system (Medtronic Inc,
Minneapolis, Minnesota), and a CUSA NXT ultrasonic tissue ablation
system (Integra Lifesciences, Plainsboro Township, New Jersey).
Preoperative Management
Four hours before induction of anesthesia, 5-ALA (Gliolan; Medac
GmbH, Hamburg, Germany) was administered orally under supervision
(20 mg/kg body weight).
Surgical Procedure
All interventions followed a strict protocol for surgery and tissue
sampling (Figure 1). Operations were performed by 3 staff neuro-
surgeons with advanced training in the use of 5-ALA. After registration of
the navigation system, the first iMRI was performed: T1-weighted
and contrast-enhanced with Dotarem (gadolinium-DOTA) (Guerbet)
20 mL/75 kg intravenously.
Tumor resection was performed by alternately operating under white
and blue light. Continuous biopsy specimens were taken and classified
according to the level of visible tissue fluorescence (0 = nonexistent, 1 =
weak, 2 = moderate, and 3 = strong). In the absence of visible
fluorescence (category 0), samples were only taken if the area clearly
appeared to be involved in the tumor despite the absence of
fluorescence. Samples for frozen section analysis were obtained at
the beginning of tumor resection. Surgery was carried out until no
fluorescent tissue remained. At this point, the second contrast-
enhanced iMRI scan was performed. In case of the absence of an
enhancing signal, complete resection was assumed, and the surgery was
terminated. When contrast enhancement was seen, that specific area
was localized with the help of the navigation system, and a detailed
reinvestigation carried out in order to reassess the absence of
fluorescence. Tissue samples were taken, and the area enhancing on
iMRI was resected under navigation guidance.
Histological Analysis
Histopathological evaluation was carried out according to the World
Health Organization 2007 diagnostic consensus criteria.26 The neuro-
pathologists were blinded to all parameters of tissue sampling, including
intraoperative location, time of sampling (before or after iMRI), and
degree of fluorescence and contrast enhancement. For each sample,
nuclear MIB-1 antibody (anti–Ki-67) staining was assessed to measure
cellular activity and determine an individual proliferation index.27 The
tissue samples were divided into 4 groups according to histological
features:
1. Tumor tissue: increased polymorphism, multinuclear cells, atypical
mitotic figures, focal or extensive necrosis, pseudopallisading, blood
vessel proliferation, bleeding.
2. Infiltration zone: markedly increased cell density and/or satellitosis,
vascular endothelial proliferation, reactive astrocytes, tumor
components.
3. Reactive central nervous system (CNS) tissue: minor increased cell
density, changes in blood vessel endothelia.
4. Unaltered brain tissue: no pathological changes.
48-Hour Postoperative MRI
All patients underwent 48-hour postoperative MRI in a 3-T MRI
scanner. Residual tumor was defined as detectable contrast enhancement
on T1-weighted series with a volume of more than 0.175 cm3. These
criteria were applied previously by other groups.13,19
Follow-up
We conducted a retrospective follow-up analysis at 40 months. Points
of interests were 6-month progression-free survival and overall survival
time.
RESULTS
Patients and Samples
Fourteen patients were operated on in total; in 13 of them, the
diagnosis of glioblastoma was confirmed (Figure 2). In 1
patient, the frozen section and definite histological analysis
revealed a diagnosis of CNS lymphoma, and the patient was
excluded from the study. One patient who did not exhibit any
5-ALA fluorescence was also excluded. In this latter patient, 5
tissue samples were taken from visibly abnormal regions, all of
which were identified histologically as solid glioblastoma
tissue.
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A total of 117 samples from the remaining 12 patients were
collected before the iMRI was carried out. Of those 117 samples,
a total of 93 were taken from fluorescent areas (25 strong, 37
moderate, and 31 weak fluorescence), and histological analysis
revealed tumor or a tumor infiltration zone in 95.7%. Twenty-four
samples were taken from tissue that did not show fluorescence, and,
in these samples, histological analysis revealed tumor or a tumor
infiltration zone in 87.5% (Table 2).
Weak fluorescence corresponded to tumor tissue in 87.1% of
cases, whereas moderate and strong fluorescence always equated
FIGURE 1. Trial protocol for surgery and tissue sampling. iMRI, intraoperative magnetic resonance imaging.
TABLE 1. Patient Seriesa
Patient
No. Age, y
Tumor
Location
Contrast-Enhancing
Tumor Remnant
on iMRI
Result on 48-h
Postoperative MRI
6-Month
Progression-Free
Survival
Second
Surgery
for Tumor
Recurrence
Postoperative
Survival Time
1 62 Right parietal Yes No contrast-enhancing tumor
remnant
Yes Yes 3 y 3 mo 5 d
2 54 Right temporal Yes No contrast-enhancing tumor
remnant
Yes 1 y 8 mo 2 d
3 67 Left occipital Yes Contrast-enhancing cystic tumor
remnant 12 · 8 · 5 mm
10 mo 24 d
4 56 Right parietal Yes No contrast-enhancing tumor
remnant
Yes 8 mo 20 d
5b 61 Right parietal Yes No contrast-enhancing tumor
remnant
8 mo 18 d
6 61 Right parietal Yes No contrast-enhancing tumor
remnant
Yes 1 y 8 mo 12 d
7 69 Right parieto-
occipital
Yes No contrast-enhancing tumor
remnant
1 y 6 mo 25 d
8 37 Right frontal Yes No contrast-enhancing tumor
remnant
1 y 1 mo 2 d
9 73 Right parieto-
occipital
Yes Small linear contrast-enhancing
tumor remnant
5 mo 23 d
10 69 Right temporal No No contrast-enhancing tumor
remnant
10 mo 14 d
11 65 Right parieto-
occipital
Yes No contrast-enhancing tumor
remnant
9 mo 15 d
12 75 Right frontal Yes No contrast-enhancing tumor
remnant
Yes 9 mo 4 d
13c X X X X X X X
14d 38 Right frontal Yes Small linear contrast-enhancing
tumor remnant
1 y 5 mo 25 d
aiMRI, intraoperative magnetic resonance imaging; MRI, magnetic resonance imaging. The patients in rows 5, 13, and 14 were excluded.
bComplete absence of intraoperative 5-aminolevulinic acid fluorescence.
cDiagnosis of central nervous system lymphoma.
dBiopsies and resection of regions that showed contrast enhancement on iMRI not possible due to location in the motor cortex.
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with tumor. The mean proliferation index (Ki-67) was 17.6% in
nonfluorescent tumor tissue and 16.7%, 17.1%, and 21.4% in
weakly, moderately, and strongly fluorescent tissue, respectively
(Table 2).
Of the 12 patients showing fluorescence intraoperatively, only
1 showed no contrast enhancement suspicious for tumor on
iMRI on completion of fluorescence-guided resection. In this
patient, no further tissue sampling was conducted, and the
FIGURE 2. Overview of patient distributions and histological results of tissue sampling. CNS, central nervous system; iMRI,
intraoperative magnetic resonance imaging; MRI, magnetic resonance imaging.
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operation was concluded. In 1 patient, contrast enhancement on
iMRI was located in the motor cortex, and no samples were
taken.
From the remaining 10 patients in whom iMRI showed
contrast-enhancing regions after the 5-ALA fluorescence–guided
surgery was completed, 28 samples were taken (Table 3). All
samples were taken under precise navigational guidance from the
area in which iMRI showed contrast enhancement. Despite
careful inspection, none of these areas showed any visible
fluorescence on second look. Of those 28 samples, solid tumor
was found in 39.3% (11/28) and an infiltration zone in 25% (7/
28) of samples, totaling 64.3% (18/28) of biopsy samples
containing tumor tissue. In 32.1% (9/28), reactively altered
brain tissue was found, and 1 sample (3.6%) showed no
pathological changes. In the 10 patients from whom these 28
samples obtained, tumor tissue was found in 8.
Sensitivity, Specificity, and Positive and Negative
Predictive Values of 5-ALA Fluorescence
For a summary of the results based on the 117 samples taken
before iMRI, see Table 4. The sensitivity of 5-ALA for detecting
tumor tissue was 81%, and the specificity was 43%. The 5-ALA
positive predictive value for tumor detection was 96% and the
negative predictive value was 12.5%.
Positive Predictive Value of iMRI Contrast
Enhancement
Based on the histological results of the 28 samples taken after
iMRI, the positive predictive value of iMRI contrast enhancement
was 64.3%.
48-Hour Postoperative MRI
Of the 10 patients in whom iMRI had shown contrast
enhancement and from whom a biopsy sample was taken before
the resection of the contrast-enhancing regions, complete resec-
tion of enhancing tumor (CRET) was achieved in 8; including the
patient in whom no residual contrast enhancement was seen on
iMRI, the CRET rate was 82%.
Follow-up
Progression-free survival at 6 months in all 11 patients in whom
completion of surgery was achieved was 36.4%. Of the 9 patients
showing CRET on 48-hour postoperative MRI, 44% were
progression free at 6 months. The 2 patients without CRET
showed progression at 6 months.
All patients received combined postoperative radiation and
temozolamide therapy. Two patients underwent a second resec-
tion due to tumor progression. The mean overall survival of these
11 patients was 15.3 months (range, 173-1193 days). The CRET
group showed a mean survival of 18.9 months, whereas the 2
TABLE 2. Histological Results of Tissue Samples Taken Before iMRI Was Performeda
Pre-MRI Samples
(13 Cases)
Total
Samples
No Fluorescence
(Total)
Positive
Fluorescence
(Total)
Fluorescence 1
(Weak)
Fluorescence 2
(Moderate)
Fluorescence 3
(Strong)
No. (%) 117 (100) 24 (100) 93 (100) 31 (100) 37 (100) 25 (100)
Histology, no. (%)
Tumor 110 (94) 21 (87.5) 89 (95.7) 27 (87.1) 37 (100) 25 (100)
Solid tumor 102 19 83 25 34 24
Infiltration
zone
8 2 6 2 3 1
Reactive CNS
tissue
7 (6) 3 (12.5) 4 (4.3) 4 (12.9) 0 0
Unaltered CNS 0 0 0 0 0 0
P/MIB-1 (Ki-67), %
PI, mean 18.16 17.60 18.15 16.70 17.13 21.44
PI, range ,1-60 ,1-50 ,1-60 ,1-60 ,1-35 8-40
aMRI, magnetic resonance imaging; CNS, central nervous system.
TABLE 3. Histological Results of Tissue Samples Taken From
Regions That Showed Contrast Enhancement on iMRIa
Postoperative iMRI Samples of
Contrast-Enhancing Regions
No. (%) 28 (100)
Histology, no. (%)
Tumor 18 (64.3)
Solid tumor 11 (39.3)
Infiltration zone 7 (25)
Reactive CNS tissue 9 (32.1)
Unaltered CNS 1 (3.6)
P/MIB-1 (Ki-67), %
PI, mean 10
PI, range 1-50
aiMRI, intraoperative magnetic resonance imaging; CNS, central nervous system.
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patients with incomplete resection survived for 10.8 and 5.8
months, respectively.
DISCUSSION
Because evidence that the degree of resection has a positive effect
on survival time is increasing, all available technicalmeans with the
potential to improve resection accuracy should be assessed and
applied. For 5-ALA fluorescence and for low-field iMRI, Class I
evidence derived from randomized, controlled trials has demon-
strated an increase in the extent of resection (EOR).13,19 We have
used 5-ALA fluorescence and iMRI routinely for glioblastoma
surgery for several years, and, with this study, we aimed to assess
the efficacy of tumor resection when both techniques are
combined.
During the initial phase of surgery, defined as that in which
tumor was resected until no suspicious areas remained under white
or blue light, we collected 93 fluorescent and 24 nonfluorescent
tissue samples. Histological examination revealed that the fluores-
cent tissue contained tumor in 95.7% and in the nonfluorescent
tissue in 87.5% of samples. However, strongly and moderately
fluorescent samples were always tumor tissue (Table 1). The high
probability of finding tumor in areas that appear to the surgeons
to be tumor under white light despite the absence of fluorescence
is in line with the findings of Roberts et al,28 who found
fluorescent samples to contain tumor in 95% of cases, whereas
nonfluorescent samples still contained tumor in 74%.
The previously described correlation of strong fluorescence
indicating solidly proliferating tumor and weak fluorescence
indicating infiltrating tumor13 was also seen our series, especially
with respect to the strongly fluorescent samples, which showed
solid tumor tissue in 23 of 24 samples.
Concurring with Stummer et al,13 Valdes et al,29 and Roberts
et al,28 we found that strong fluorescence was associated with
a higher degree of malignancy (MIB-1 index) than weak or
moderate fluorescence (Table 1). However, it must be noted that
the mean MIB-1 index of our samples without fluorescence
(17.6%) was similar to that in samples with weak or moderate
fluorescence (16.7% and 17.1%, respectively). The variability of
our individual MIB-1 values (even within the same tumor of
a single patient) was very large in all categories of fluorescence,
rendering statistical analysis nonsignificant between all groups.
The reasons for the high probability of nonfluorescent tissue,
which appears suspicious for tumor under white light, ultimately
being confirmed to be tumor or a tumor infiltration zone, are
probably several. It has been discussed that shading of the surgical
field or overlying nonfluorescent layers of tissue, blood, or necrotic
debris prevent the visualization of fluorescing tumor
beneath.5,15,28,30,31 Although we cannot rule out these scenarios,
they are unlikely to be the main cause of the low negative
predictive value of 5-ALA fluorescence (Figure 3). In our series,
each case was operated on and examined for fluorescence by 2
experienced neurosurgeons, and great care was taken not to miss
any fluorescent tissue. All areas that showed contrast enhance-
ment on iMRI were carefully reinspected under navigation
guidance, and no fluorescence was found. One of our histolog-
ically proven glioblastoma patients was completely fluorescence
negative, despite double-checking by 2 pathologists and verifi-
cation by the nursing staff that the 5-ALA was ingested
preoperatively. This tumor did not contain large necrotic zones,
and we did not encounter any intraoperative technical difficulties.
Similar cases of a total absence of fluorescence have been
previously reported,30,32,33 and the reason remains unknown.
Presumably, some tumor tissue emits levels of fluorescence that
cannot be perceived by the surgeons with the current technical
setup. This was recently confirmed by Stummer et al,31 who
detected spectrometric fluorescence in marginal tumor tissue that
did not show intraoperative, macroscopic fluorescence.
On completion of tumor resection without leaving any traces of
fluorescent tissue, iMRI unexpectedly revealed contrast enhance-
ment suspicious of remnant tumor in 11 of 12 patients (91.7%).
The contrast-enhancing areas weremostly thin and linear, whereas
small nodular enhancements (as seen in Figure 4) were the
exception. Our rate of contrast-enhancing areas on iMRI on
completion of the 5-ALA–guided resection was remarkably high
and was probably related to the fact that we considered even small
contrast-enhancing linings as suspicious for tumor remnant. A
proportion of these thin rims along the surface of the resection
TABLE 4. Sensitivity, Specificity, Positive Predictive Value (ie, the Probability of Tumor DetectionWhen Fluorescence Is Positive) and Negative
Predictive Value (ie, the Probability That Nonfluorescent Tissue Is Truly Negative for the Presence of Tumor) of 5-ALA Fluorescencea
Preoperative iMRI
Total (N = 117)
Condition Positive
(Tumor/Infiltrated Tissue)
(n = 110)
Condition Negative
(Reactive/Normal Tissue)
(n = 7)
Test positive, N = 93
(positive fluorescent)
A, true positive, no = 89 B, false positive, n = 4 PPV, (A/A 1 B) 0.96 = 96%
Test negative, N = 24
(negative fluorescent)
C, false negative, n = 21 D, true negative, n = 3 NPV, (D/C 1 D), 0.125 = 12.5%
Sensitivity, (A/A 1 C), 0.81 = 81% Specificity, (D/D 1 B), 0.43 = 43%
a5-ALA, 5-aminolevulinic acid; iMRI, intraoperative magnetic resonance imaging; PPV, positive predictive value; NPV, negative predictive value.
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cavity may have been related to surgery-induced breakdown of
the blood-brain barrier and subsequent contrast enhancement on
iMRI. Under careful examination, none of these areas showed
signs of fluorescence during the process of taking biopsy samples
and subsequent tumor removal with ultrasonic aspiration.
Because approximately two-thirds these samples, obtained from
8 of 10 patients, contained either tumor (39.3%) or a tumor
infiltration zone (25%), these figures have great implication. The
data prove that, despite an optimal technical setup, some tumor
tissue might remain undetected because either it does not exhibit
fluorescence or because the strength of fluorescence cannot be
perceived with currently available means. Bearing in mind the
one-third probability of iMRI enhancement not corresponding
with tumor tissue, we conclude that resection of these areas
should only be carried out when functional deficits are highly
unlikely.
To our knowledge, this is the first study based on histological
sampling to assess the predictive value of iMRI after completion of
FIGURE 3. Tumor appearance under white light (left) and blue light, showing 5-ALA induced fluorescence (right). Note that
fluorescence is reduced in areas covered with blood and also in some areas that are not blood covered (white arrows). 5-ALA,
5-aminolevulinic acid.
FIGURE 4. Intraoperative MRI of the case illustrated in Figure 3. Identical axial slice before (left) and after (right) resection
guided by 5-ALA fluorescence. Note the contrast-enhancing area (arrow) suspicious for remnant tumor. Two tissue samples were
taken from this area, which also on second inspection did not show any 5-ALA fluorescence. Both tissue samples revealed a tumor
infiltration zone with PI (MIB-1/Ki-67) indices of 2% and 10%, respectively. Postoperative 1.5-T MRI did not show any
contrast-enhancing tumor remnant. 5-ALA, 5-aminolevulinic acid; MRI, magnetic resonance imaging.
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5-ALA fluorescence–guided glioblastoma resection. In 2011,
Tsugu et al33 reported a synergistic effect of the combination of
5-ALA and iMRI for glioma surgery. However, their EOR on
postoperative 1.5-T MRI was only marginally different between
the groups of fluorescence only (91.8%) vs fluorescence plus
subsequent iMRI (92.6%), and, in cases of absence of intra-
operative fluorescence, they found iMRI to be most useful in
increasing EOR. Because the study lacked histological data, the
predictive values for tumor tissue of both methods remains
unknown. Eyupoglu et al34 reported an improved EOR by
combining 5-ALA–aided resection and subsequent iMRI in
patients with malignant glioma localized close to eloquent areas,
with residual tumor seen on iMRI in 32.4% of patients on
completion of 5-ALA– guided resection. They thought that
missing fluorescent areas were mainly attributable to layers of
overlying, nonfluorescent tissue. Coburger et al35 performed
white-light GTR (not using 5-ALA fluorescence) in high-grade
glioma surgery and then took samples from areas showing 5-ALA
florescence and from structures showing contrast enhancement
on 1.5-T iMRI. For the detection of pathological tissue,
particularly at the border of the resection cavity, they reported
a significant advantage of 5-ALA fluorescence over iMRI, with
higher rates of sensitivity (91% for 5-ALA vs 66% for iMRI) and
specificity (80% for 5-ALA vs 60% for iMRI).
Based on the 48-hour postoperative MRI, we achieved CRET
in 82% of cases. This is slightly better than the rates reported by
Stummer et al13 using 5-ALA florescence (65%) and slightly
below the CRET rates reported by Senft et al19 (96%). The latter
refers to a randomized trial to assess the efficacy of low-field iMRI
(PoleStar) in high-grade glioma surgery without the use of 5-ALA
fluorescence.
Despite the combined use of 5-ALA fluorescence and iMRI
leading to good CRET rates on postoperative MRI, the 6-month
progression-free survival rate of our study was not improved (36.4%
vs 41% in the 5-ALA group reported by Stummer et al13). Neither
was overall survival prolonged in our cohort (17.1 months in the
,55 age group and 14.9 months in those older than 55 vs 18 and
14.1 months, respectively as reported by Stummer et al13).
However, it should be noted that we had a significantly lower
rate of surgical reintervention for tumor recurrence (18.1% vs
55%-82%13), and this is highly likely to have influenced overall
survival time. Our low reoperation rate is probably due to a variety
of factors, including a tendency to refrain from repeat surgery at the
cost of surgery-induced neurological deficits.
Limitations
Our study was limited by small patient numbers and the
surgeon-dependant assessment of fluorescence. Even when apply-
ing meticulous effort to search for fluorescence, the currently
commercially available adaptations of the microscope will fail to
detect very low fluorescence levels, and the assessment is non-
quantitative. The question of whether the accuracy of iMRI
assessment of remnant tumor may be improved by using higher
field iMRI is the subject of ongoing research. Data directly
comparing imaging information on low- vs high-field iMRI are
scarce. Hirschl et al36 retrospectively compared findings on low-
field iMRI (0.12 T Polestar) and postoperative 1.5-T MRI for
glial tumors. They found low-field MR to have a sensitivity of
82% and a specificity of 95% in detecting residual tumor.
Bergsneider et al37 retrospectively compared the extent of
volumetric resection of a mixed group of high- and low-grade
gliomas that were either operated on with intraoperative guidance
from a 0.2-T or a 1.5-T scanner. They found no difference
between the groups.
Resecting fluorescently stained tumor tissue and the application
of iMRI for residual tumor detection are 2methods that have been
proved to improve the prognosis of glioblastoma multiforme. By
combining both methods, we were not able to show a further
extension of survival time, but we did shine light on the limitations
and advantages of both methods. 5-ALA fluorescence lacks
sensitivity in defining infiltrating tumor and also demonstrates
a low negative prediction accuracy in cases of tissue macroscop-
ically appearing to be tumor. On the other hand, iMRI is able to
detect tumor tissue located beyond the current technical range of
5-ALA visualization, albeit with a 35.7% risk of overresection.
Refinedmethods for the detection of tumor fluorescence, as well as
high resolution and functional intraoperative imaging, will
continue to improve tumor visualization and thus maximize
tumor resection while minimizing risk. Curing glioblastoma is not
achievable with surgical means alone, but precise resection is likely
to improve the efficacy of adjuvant therapeutic regimes.
CONCLUSION
Not all glioblastoma tissue exhibits intraoperative 5-ALA
fluorescence and not all areas of iMRI contrast enhancement
represent tumor. iMRI performed after complete resection of 5-
ALA fluorescent tissue shows contrast-enhancing regions suspi-
cious for tumor in a high percentage of cases (91.6%), whereas
these regions in fact contain tumor in only 64.3%. This reveals the
sensitivity limitations of 5-ALA fluorescence and the rather low
predictive value of iMRI for remnant tumor. iMRI is a suitable
supplementary method for fluorescence-guided glioblastoma
surgery, but the extended resection of iMRI contrast-enhancing
areas must be considered with caution in eloquent sites.
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